%0 Journal Article %@ 1531-8249 %A Tsivgoulis, G %A Wilson, D %A Katsanos, AH %A Sargento-Freitas, J %A Marques-Matos, C %A Azevedo, E %A Adachi, T %A von der Brelie, C %A Aizawa, Y %A Abe, H %A Tomita, H %A Okumura, K %A Hagii, J %A Seiffge, DJ %A Lioutas, V-A %A Traenka, C %A Varelas, P %A Basir, G %A Krogias, C %A Purrucker, JC %A Sharma, VK %A Rizos, T %A Mikulik, R %A Sobowale, OA %A Barlinn, K %A Sallinen, H %A Goyal, N %A Yeh, S-J %A Karapanayiotides, T %A Wu, TY %A Vadikolias, K %A Ferrigno, M %A Hadjigeorgiou, G %A Houben, R %A Giannopoulos, S %A Schreuder, FHBM %A Chang, JJ %A Perry, LA %A Mehdorn, M %A Marto, J-P %A Pinho, J %A Tanaka, J %A Boulanger, M %A Salman, RA-S %A Jäger, HR %A Shakeshaft, C %A Yakushiji, Y %A Choi, PMC %A Staals, J %A Cordonnier, C %A Jeng, J-S %A Veltkamp, R %A Dowlatshahi, D %A Engelter, ST %A Parry-Jones, AR %A Meretoja, A %A Mitsias, P %A Alexandrov, AV %A Ambler, G %A Werring, DJ %D 2018 %F discovery:10057877 %J Annals of Neurology %K haematoma volume, individual patient data meta-analysis, intracerebral haemorrhage, non-vitamin K antagonist, outcome, vitamin K antagonist %N 5 %P 694-704 %T Neuroimaging and clinical outcomes of oral anticoagulant associated ICH %U https://discovery.ucl.ac.uk/id/eprint/10057877/ %V 84 %X OBJECTIVE: Whether intracerebral haemorrhage (ICH) associated with non-vitamin K antagonist oral anticoagulants (NOAC-ICH) has a better outcome compared to ICH associated with vitamin-K antagonists (VKA-ICH) is uncertain. METHODS: We performed a systematic review and individual patient data meta-analysis of cohort studies comparing clinical and radiological outcomes between NOAC-ICH and VKA-ICH patients. The primary outcome measure was 30-day all-cause mortality. All outcomes were assessed in multivariable regression analyses adjusted for age, sex, ICH location and intraventricular haemorrhage extension. RESULTS: We included 7 eligible studies comprising 219 NOAC-ICH and 831 VKA-ICH patients (mean age:77 years,52.5% females). The 30-day mortality was similar between NOAC-ICH and VKA-ICH (24.3% vs. 26.5%; HR=0.94, 95%CI: 0.67 to 1.31). However, in multivariable analyses adjusting for potential confounders, NOAC-ICH was associated with: lower admission National Institutes of Health Stroke Scale (NIHSS) score (linear regression coefficient=-2.83, 95%CI:-5.28 to -0.38); lower likelihood of severe stroke (NIHSS>10 points) on admission (OR=0.50, 95%CI: 0.30 to 0.84); and smaller baseline haematoma volume (linear regression coefficient=-0.24,95%CI:-0.47 to -0.16). The two groups did not differ in the likelihood of: baseline haematoma volume less than 30cm3 (OR=1.14, 95%CI: 0.81 to 1.62); haematoma expansion (OR=0.97, 95%CI: 0.63 to 1.48); in-hospital mortality (OR=0.73,95%CI: 0.49 to 1.11); functional status at discharge (common OR=0.78, 95%CI: 0.57 to 1.07); or functional status at three months (common OR=1.03, 95%CI: 0.75 to 1.43). INTERPRETATION: Although functional outcome at discharge, one month or three months were comparable after NOAC-ICH and VKA-ICH, patients with NOAC-ICH had smaller baseline haematoma volumes and less severe acute stroke syndromes. %Z This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions.